Re: Biogen looks to FDA for approval of early Alzheimers drug.
in response to
by
posted on
Oct 22, 2019 10:56AM
Bear,
you don't give weight to the "rigorous academic requirements in confirming the primary endpoint" quote from Don McCaffrey in his Sept 30 conference call?
I interpreted that to suggest that the trial failed on purely statistical grounds...i.e. more patient years would have got us to meeting endpoints. How else can one interpret it?
Iconoclast